- Home
- HSPO vs CRBU Comparison
HSPO vs CRBU Comparison
Compare HSPO & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- CRBU
- Stock Information
- Founded
- HSPO 2014
- CRBU 2011
- Country
- HSPO United States
- CRBU United States
- Employees
- HSPO N/A
- CRBU N/A
- Industry
- HSPO Blank Checks
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- HSPO Finance
- CRBU Health Care
- Exchange
- HSPO Nasdaq
- CRBU Nasdaq
- Market Cap
- HSPO 49.4M
- CRBU 93.0M
- IPO Year
- HSPO 2022
- CRBU 2021
- Fundamental
- Price
- HSPO $11.79
- CRBU $0.79
- Analyst Decision
- HSPO
- CRBU Strong Buy
- Analyst Count
- HSPO 0
- CRBU 5
- Target Price
- HSPO N/A
- CRBU $10.60
- AVG Volume (30 Days)
- HSPO 294.0
- CRBU 1.0M
- Earning Date
- HSPO 01-01-0001
- CRBU 05-16-2025
- Dividend Yield
- HSPO N/A
- CRBU N/A
- EPS Growth
- HSPO N/A
- CRBU N/A
- EPS
- HSPO 0.27
- CRBU N/A
- Revenue
- HSPO N/A
- CRBU $9,994,000.00
- Revenue This Year
- HSPO N/A
- CRBU N/A
- Revenue Next Year
- HSPO N/A
- CRBU $163.34
- P/E Ratio
- HSPO $44.35
- CRBU N/A
- Revenue Growth
- HSPO N/A
- CRBU N/A
- 52 Week Low
- HSPO $10.87
- CRBU $0.66
- 52 Week High
- HSPO $12.41
- CRBU $4.21
- Technical
- Relative Strength Index (RSI)
- HSPO 46.31
- CRBU 44.91
- Support Level
- HSPO $11.78
- CRBU $0.77
- Resistance Level
- HSPO $11.90
- CRBU $0.91
- Average True Range (ATR)
- HSPO 0.02
- CRBU 0.08
- MACD
- HSPO -0.02
- CRBU 0.01
- Stochastic Oscillator
- HSPO 4.76
- CRBU 32.97
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.